What is the recommended acute management and intervention strategy for a hemorrhagic stroke?

Hemorrhagic Stroke: Acute Management and Intervention Strategy

Treat hemorrhagic stroke as a medical emergency requiring immediate CT imaging to confirm diagnosis, aggressive blood pressure reduction to systolic <140 mmHg within 1 hour (if presenting SBP >150 mmHg and within 6 hours of onset), rapid reversal of any coagulopathy, and neurosurgical consultation for cerebellar hemorrhages or obstructive hydrocephalus. 1, 2

Immediate Recognition and Assessment

Hemorrhagic stroke accounts for 10-15% of all strokes but carries 30-40% early mortality, making it the deadliest stroke subtype 1, 2. Patients must be evaluated immediately by physicians with expertise in hyperacute stroke management 3.

Initial Diagnostic Workup

• Obtain non-contrast CT or MRI immediately to confirm intracerebral hemorrhage (ICH), determine location, and quantify hematoma volume 3, 1
• Perform CT angiography, MR angiography, or catheter angiography to exclude underlying vascular lesions (aneurysm, arteriovenous malformation) 3
• Measure platelet count, PT/INR, and aPTT immediately, and obtain detailed anticoagulant/antiplatelet medication history 3, 1
• Assess for clinical signs of increased intracranial pressure (altered consciousness, pupillary changes, Cushing's triad) 3
• Use NIHSS for awake/drowsy patients or Glasgow Coma Scale for obtunded patients to establish baseline severity 3

Blood Pressure Management

This is the single most critical modifiable intervention in acute ICH.

Acute Phase Protocol (First 24 Hours)

For patients presenting within 6 hours of symptom onset with SBP >150 mmHg and no contraindication to acute BP treatment:

• Target systolic BP <140 mmHg achieved within 1 hour 2, 4
• The 2022 AHA guideline supports intensive lowering to 130-140 mmHg range based on pooled data from INTERACT2 and ATACH-II 2, 4

Critical caveats:

• Avoid rapid, excessive BP drops >70 mmHg in the first hour—this associates with poor outcomes 4
• The "sweet spot" is a reduction of 30-45 mmHg over 1 hour 4
• Assess BP every 15 minutes until stabilized 3
• Use titratable intravenous agents (nicardipine, labetalol, clevidipine) rather than fixed-dose regimens 1

Patients with Baseline SBP >220 mmHg

Exercise particular caution—these patients may be at higher risk for complications with aggressive lowering 2, 4. Still target <140 mmHg but monitor closely for hypoperfusion.

Coagulopathy Reversal

Speed is essential—reversal should begin immediately upon diagnosis, not after laboratory confirmation.

Warfarin-Associated ICH

• Administer prothrombin complex concentrate (PCC) immediately plus intravenous vitamin K 5, 2
• Do NOT use fresh frozen plasma—it requires large volumes and delays reversal 5
• Target INR <1.4 within 4 hours 2

Direct Oral Anticoagulants (DOACs)

• Idarucizumab for dabigatran (specific reversal agent) 2
• Andexanet alfa for factor Xa inhibitors (apixaban, rivaroxaban) 2
• If specific reversal unavailable, consider PCC 2

Antiplatelet Agents

• Platelet transfusion is NOT routinely recommended and may worsen outcomes 2
• Consider only in specific circumstances (planned urgent surgery, platelet count <100,000/mm³) 2

Surgical Intervention

Absolute Indications

Cerebellar hemorrhage with:

• Brain stem compression
• Obstructive hydrocephalus
• Neurological deterioration

Surgical decompression and evacuation is life-saving 6, 2

Hydrocephalus Management

• External ventricular drainage for acute obstructive hydrocephalus 6, 2
• Monitor intracranial pressure continuously if EVD placed 3

Supratentorial ICH

Evidence remains mixed for routine evacuation of supratentorial hemorrhages. The 2022 AHA guideline suggests:

• Minimally invasive surgery may be considered for selected patients 2
• Large hemispheric infarctions causing herniation: decompressive craniectomy can be life-saving but survivors have severe residual deficits 6

Management of Increased Intracranial Pressure

If clinical deterioration from elevated ICP:

• Elevate head of bed 20-30 degrees 6
• Osmotherapy (mannitol or hypertonic saline) 6
• Hyperventilation (temporary measure only) 6
• Corticosteroids are NOT recommended for cerebral edema in ICH 6

Avoid factors that exacerbate ICP: hypoxia, hypercarbia, hyperthermia 6

Seizure Management

• Seizures occur in 4-8% of ICH patients in first 24 hours 6
• Treat active seizures with standard anticonvulsants 6
• Prophylactic anticonvulsants are NOT recommended for patients without seizures 6

Critical Monitoring Parameters

First 24 hours:

• Neurological assessment using validated scale (CNS score) at least hourly 3
• Blood pressure every 15 minutes until stable, then hourly 3
• Watch for hematoma expansion (occurs in 30-40% of patients) 3
• Risk factors for expansion: early presentation (<6 hours), anticoagulation, "spot sign" on CTA 3

Fluid Management

• Maintain euvolemia—avoid both hypovolemia and hypervolemia 3, 5
• Use isotonic crystalloids (0.9% saline)—avoid hypotonic solutions like D5W which worsen edema 6, 5
• Avoid synthetic colloids, gelatins, and Ringer's lactate (hypotonic when measured as real osmolality) 5

Common Pitfalls to Avoid

1. Delaying coagulopathy reversal while waiting for laboratory confirmation—start reversal immediately
2. Using fresh frozen plasma instead of PCC for warfarin reversal—wastes critical time
3. Overly aggressive BP lowering (>70 mmHg drop in first hour)—associated with worse outcomes
4. Prophylactic anticonvulsants—not beneficial and may impair recovery
5. Withholding aggressive care based on initial severity—avoid self-fulfilling prophecy of poor prognosis 7
6. Routine platelet transfusion for antiplatelet-associated ICH—may worsen outcomes

Transfer Considerations

If neurosurgical capability unavailable:

• Stabilize BP and reverse coagulopathy BEFORE transfer 5
• Never transfer hypotensive, actively bleeding patients 5
• Maintain SBP <160 mmHg during transport (unsecured aneurysm if SAH) 5

This algorithmic approach prioritizes the interventions with strongest evidence for reducing mortality and improving functional outcomes in hemorrhagic stroke.